McMMAF is primarily utilized in the field of targeted cancer therapy, specifically in the development of antibody-drug conjugates (ADCs). It functions as a potent cytotoxic agent that is linked to monoclonal antibodies, which are designed to recognize and bind to specific antigens on cancer cells. Once the ADC binds to the target cell, McMMAF is internalized and released, leading to cell death by disrupting microtubule function and inhibiting cell division. This approach allows for the precise delivery of the cytotoxic payload to cancer cells, minimizing damage to healthy tissues and reducing systemic side effects. McMMAF is particularly valuable in treating hematological malignancies and solid tumors where targeted therapy is essential for improving treatment outcomes.